Neurodegeneration with Brain Iron Accumulation (NBIA) Cell Models for Research

NBIA comprises a group of rare inherited neurodegenerative disorders characterized by iron accumulation in the basal ganglia. Global incidence is estimated at 1-3 per million individuals, with prevalence varying by subtype (Orphanet, 2023). The most common subtype, PKAN (PANK2-associated neurodegeneration), accounts for approximately 35-50% of NBIA cases. Other subtypes include PLAN (PLA2G6), MPAN (C19orf12), BPAN (WDR45), and aceruloplasminemia (CP). Age of onset ranges from early childhood to adulthood, with rapid progression leading to severe disability and premature death. There is no cure; management is supportive. Five-year survival after diagnosis varies by subtype, with PKAN showing a median survival of 10-15 years post-onset (NCI, 2023). Key risk factors include family history and specific genetic mutations. Due to rarity, epidemiological data are limited, but patient registries (e.g., NBIA Disorders Association) provide valuable insights.

NBIA serves as a paradigm for studying iron metabolism, mitochondrial dysfunction, and neurodegeneration. Its monogenic nature (over 15 genes identified) makes it ideal for mechanistic studies. Public datasets such as ClinVar, gnomAD, and GEO provide mutation and expression data. Open questions include: How do mutations in iron-handling proteins lead to regional iron deposition? What are the molecular links between iron accumulation and neuronal death? Subtypes offer distinct pathways: PANK2 in CoA synthesis, PLA2G6 in phospholipid remodeling, CP in iron oxidation. These pathways are conserved and can be modeled in cell lines, enabling high-throughput screens and functional genomics.

Although NBIA is not a cancer, the term carcinogenic is replaced with pathogenic pathways. Key pathways include:

• • Iron homeostasis dysregulation:

1. Mutations in PANK2 lead to impaired CoA synthesis, affecting mitochondrial iron-sulfur cluster biogenesis.

2. PLA2G6 mutations cause phospholipid remodeling defects, altering mitochondrial membrane integrity and iron handling.

3. CP mutations impair ferroxidase activity, leading to iron accumulation in tissues.

• • Mitochondrial dysfunction:

1. Defective oxidative phosphorylation and increased reactive oxygen species (ROS).

2. Impaired mitophagy leads to accumulation of damaged mitochondria.

• • Lipid peroxidation and ferroptosis:

1. Iron overload catalyzes lipid peroxidation, triggering ferroptotic cell death.

2. Reduced glutathione peroxidase 4 (GPX4) activity exacerbates lipid damage.

• • Neuroinflammation:

1. Microglial activation and cytokine release contribute to neuronal loss.

2. Iron-induced oxidative stress activates NF-kB and NLRP3 inflammasome.

Data from ClinVar, COSMIC, and published cohorts (e.g., NBIA registry).

Key networks and nodes:

• • Iron regulatory network:
• • IRP1/IRP2 (iron regulatory proteins) sense iron levels and regulate ferritin and transferrin receptor expression.
• • Hepcidin-ferroportin axis controls systemic iron export.
• • Mitochondrial quality control:
• • PINK1/Parkin-mediated mitophagy is impaired in NBIA models.
• • OPA1 and MFN2 regulate mitochondrial dynamics.
• • Oxidative stress response:
• • NRF2/ARE pathway is activated but insufficient to counteract ROS.
• • NF-kB drives pro-inflammatory cytokine expression.
• • Ferroptosis pathway:
• • GPX4 and system xc- (SLC7A11) are critical regulators.
• • ACSL4 promotes lipid peroxidation.
• • Autophagy-lysosomal pathway:
• • WDR45 mutations impair autophagosome formation.
• • TFEB dysregulation affects lysosomal biogenesis.

Organoids: Midbrain organoids derived from iPSCs can model iron accumulation and neurodegeneration, offering 3D architecture and cell-type diversity. Advantages include better representation of brain microenvironment and disease progression.

Animal models for NBIA:

• • Pank2 knockout mouse: Develops mild motor deficits and iron accumulation in basal ganglia.
• • Pla2g6 knockout mouse: Shows neurodegeneration, iron deposition, and mitochondrial dysfunction.
• • Cp knockout mouse: Exhibits iron overload in liver and brain.
• • Wdr45 knockout mouse: Displays impaired autophagy and cognitive deficits.
• • Induced models: Stereotaxic injection of iron or ferric ammonium citrate into rat brain to mimic focal iron accumulation.
• • PDX models: Not applicable as NBIA is not a cancer; however, patient-derived xenografts of fibroblasts or iPSCs can be used.

These models are valuable for preclinical testing but have limitations in recapitulating full human phenotype.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise NBIA mutations. Examples include:

• • PANK2 knockout SH-SY5Y: Generated via CRISPR to study CoA metabolism and mitochondrial function.
• • PLA2G6 knock-in HEK293T: Introduction of patient-specific missense mutations (e.g., p.R741Q) to assess lipid remodeling.
• • CP knockout HepG2: To model aceruloplasminemia and iron export defects.
• • WDR45 knockout iPSCs: Differentiated into neurons to study autophagy impairment.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use tools. These models undergo rigorous validation (e.g., Sanger sequencing, Western blot) to ensure knockout/knock-in efficiency. They are essential for drug discovery, target validation, and functional genomics.

Knockout and knock-in lines validate gene function in NBIA pathways. For example:

• • PANK2 knockout cells show reduced CoA levels and impaired mitochondrial respiration, confirming its role in PKAN.
• • PLA2G6 knockout cells exhibit increased lipid peroxidation and sensitivity to ferroptosis inducers.
• • CP knockout cells accumulate intracellular iron and have reduced ferroxidase activity.

These models enable high-throughput screens to identify modifiers of disease phenotypes.

Isogenic pairs (wild-type vs. mutant) are used for drug screening. For example:

• • PANK2 knockout vs. isogenic control: Screen for compounds that rescue CoA levels or mitochondrial function.
• • PLA2G6 mutant vs. wild-type: Test ferroptosis inhibitors (e.g., ferrostatin-1) for neuroprotection.
• • CP knockout vs. wild-type: Evaluate iron chelators (e.g., deferiprone) for reducing iron accumulation.

Resistance modeling: Gene-edited cells can be used to study resistance to iron chelators or antioxidants, identifying combination therapies.

CRISPR synthetic lethality screens in NBIA models can identify genetic dependencies. For example:

• • Genome-wide knockout screens in PANK2-null cells reveal synthetic lethal interactions with genes in CoA synthesis or iron metabolism.
• • These screens uncover potential biomarkers for patient stratification or therapeutic targets.

Additionally, gene-edited reporter lines (e.g., GFP-tagged ferritin) enable live-cell imaging of iron dynamics, facilitating biomarker discovery.